Overview#
William Blair has recently started covering Cardinal Health Inc. (NYSE: CAH) with an outperform rating. This indicates that the firm believes the stock will perform better than the market average.
Valuation Insights#
Analyst Max Smock pointed out that Cardinal Health is currently trading at 18.2 times the estimated adjusted earnings per share for 2026. This is considered a premium compared to its historical performance. The stock's price-to-earnings (P/E) ratio stands at 29.14, but it has a price-to-earnings growth (PEG) ratio of 0.97. A PEG ratio below 1 suggests that the stock may be undervalued relative to its expected earnings growth.
Competitive Position#
Smock noted that Cardinal Health's valuation is slightly higher than that of Cencora, a competitor, but lower than McKesson. The premium valuation is justified by the company's transformation into a healthcare services and technology partner, expanding beyond its traditional pharmaceutical distribution business. According to analysis, Cardinal Health is considered undervalued based on its fair value assessment and holds a solid financial health score of 3.18 out of 5.
Recent Developments#
In recent news, Cardinal Health has experienced several significant changes. Evercore ISI raised its price target for the company from $250 to $260, maintaining an outperform rating after the latest earnings report. UBS also reiterated a buy rating with the same price target, while Leerink Partners set a higher target of $275, citing strong market demand. Additionally, Cardinal Health announced Patricia A. Hemingway Hall as the new board chair, succeeding Gregory B. Kenny, and noted that Senior Vice President Mary Scherer will retire in February 2027, with a search for her successor currently underway. These updates reflect the company's ongoing strategic and operational efforts.